Cargando…

Efficacy and safety of anti‐amyloid‐β immunotherapy for Alzheimer's disease: a systematic review and network meta‐analysis

To review the optimality and safety of different anti‐Amyloid‐β(Aβ) immunotherapies for Alzheimer's disease (AD). Published randomized controlled trials were comprehensively reviewed from electronic databases (Cochrane library, Embase, Pubmed, and Google scholar). Pooled outcomes as mean differ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mo, Jia‐Jie, Li, Jin‐yu, Yang, Zheng, Liu, Zhou, Feng, Jin‐Shan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740249/ https://www.ncbi.nlm.nih.gov/pubmed/29296624 http://dx.doi.org/10.1002/acn3.469

Ejemplares similares

Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
por: Song, Chenghuan, et al.
Publicado: (2022)

Comparison of Tau and Amyloid-β Targeted Immunotherapy Nanoparticles for Alzheimer’s Disease
por: Mashal, Yara, et al.
Publicado: (2022)

Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β
por: Vogt, Anne-Cathrine S., et al.
Publicado: (2023)

Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer’s Disease and Cerebral Amyloid Angiopathy
por: DiFrancesco, Jacopo C., et al.
Publicado: (2015)

Polymorphic Structures of Alzheimer's β-Amyloid Globulomers
por: Yu, Xiang, et al.
Publicado: (2011)

Anti-Amyloid Immunotherapies for Alzheimer’s Disease: A 2023 Clinical Update
por: Yadollahikhales, Golnaz, et al.
Publicado: (2023)

Immunotherapy for the treatment of Alzheimer’s disease: amyloid-β or tau, which is the right target?
por: Castillo-Carranza, Diana L, et al.
Publicado: (2013)

Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer’s disease
por: Lambracht-Washington, Doris, et al.
Publicado: (2013)

Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?
por: Moreth, Jens, et al.
Publicado: (2013)

Bapineuzumab Alters Aβ Composition: Implications for the Amyloid Cascade Hypothesis and Anti-Amyloid Immunotherapy
por: Roher, Alex E., et al.
Publicado: (2013)

Cerebrospinal Fluid β-Amyloid(1–42) Levels in the Differential Diagnosis of Alzheimer’s Disease—Systematic Review and Meta-Analysis
por: Mo, Jin-A, et al.
Publicado: (2015)

Amyloid-ß-directed immunotherapy for Alzheimer's disease
por: Lannfelt, L, et al.
Publicado: (2014)

Amyloid-beta immunotherapy: the hope for Alzheimer disease?
por: Barrera-Ocampo, Alvaro, et al.
Publicado: (2016)

Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies
por: Crespi, Gabriela A. N., et al.
Publicado: (2015)

Prescribing anti‐amyloid immunotherapies to treat Alzheimer's disease: Fully informing patient decisions
por: Greenberg, Barry D., et al.
Publicado: (2023)

The efficacy and safety of anti-Aβ agents for delaying cognitive decline in Alzheimer’s disease: a meta-analysis
por: Li, Jiaxuan, et al.
Publicado: (2023)

The biochemical aftermath of anti-amyloid immunotherapy
por: Maarouf, Chera L, et al.
Publicado: (2010)

Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise
por: van Dyck, Christopher H.
Publicado: (2017)

A Peptide That Binds Specifically to the β-Amyloid of Alzheimer's Disease: Selection and Assessment of Anti-β-Amyloid Neurotoxic Effects
por: Wang, Fang, et al.
Publicado: (2011)

Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease
por: Weller, Roy O, et al.
Publicado: (2009)

Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease
por: Lannfelt, Lars, et al.
Publicado: (2014)

Efficacy and safety of sublingual immunotherapy for allergic rhinitis: A network meta-analysis
por: Ji, Zao, et al.
Publicado: (2023)

Amyloid PET: A Questionable Single Primary Surrogate Efficacy Measure on Alzheimer Immunotherapy Trials
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022)

In Vivo Detection of Amyloid Plaques by Gadolinium-Stained MRI Can Be Used to Demonstrate the Efficacy of an Anti-amyloid Immunotherapy
por: Santin, Mathieu D., et al.
Publicado: (2016)

Amyloid-β (Aβ) immunotherapy induced microhemorrhages are associated with activated perivascular macrophages and peripheral monocyte recruitment in Alzheimer’s disease mice
por: Taylor, Xavier, et al.
Publicado: (2023)

β-Amyloid Degradation and Alzheimer's Disease
por: Wang, Deng-Shun, et al.
Publicado: (2006)

Mitochondria, Amyloid β, and Alzheimer's Disease
por: Readnower, Ryan D., et al.
Publicado: (2011)

The Amyloid-β Pathway in Alzheimer’s Disease
por: Hampel, Harald, et al.
Publicado: (2021)

Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
por: Fedele, Ernesto
Publicado: (2023)

Interactions between Amyloid-β and Hemoglobin: Implications for Amyloid Plaque Formation in Alzheimer's Disease
por: Chuang, Jia-Ying, et al.
Publicado: (2012)

Within-patient correspondence of amyloid-β and intrinsic network connectivity in Alzheimer’s disease
por: Myers, Nicholas, et al.
Publicado: (2014)

Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: a systematic review and network Meta-analysis
por: Gao, Tian-Tian, et al.
Publicado: (2022)

Can Anti–β-amyloid Monoclonal Antibodies Work in Autosomal Dominant Alzheimer Disease?
por: Imbimbo, Bruno P., et al.
Publicado: (2020)

Initial failures of anti-tau antibodies in Alzheimer’s disease are reminiscent of the amyloid-β story
por: Imbimbo, Bruno P., et al.
Publicado: (2022)

The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy
por: Sengupta, Urmi, et al.
Publicado: (2016)

Likely a matter of time for Amyloid-β immunotherapy
por: Cunha, Andreia
Publicado: (2021)

Responder analyses for anti-amyloid immunotherapies for Alzheimer’s disease: a paradigm shift by regulatory authorities is urgently needed
por: Salemme, Simone, et al.
Publicado: (2023)

Open peer commentary on “Prescribing anti‐amyloid immunotherapies to treat Alzheimer's disease: Fully informing patient decisions”
por: Gandy, Sam
Publicado: (2023)

LISPRO mitigates β-amyloid and associated pathologies in Alzheimer’s mice
por: Habib, Ahsan, et al.
Publicado: (2017)

The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials
por: Wu, Wenxue, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9on8n53ovs34c879ql51vjo0n0